Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements review identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://josht085opq5.blogsmine.com/profile